In-cell cryo-electron tomography reveals differential effects of type I and type II kinase inhibitors on LRRK2 filament formation and microtubule association
Curation statements for this article:-
Curated by eLife
**eLife Assessment
**
This study reports important findings by showing that two classes of kinase inhibitors, which stabilise the LRRK2 enzyme in either an active (Type I) or inactive state (Type II), have distinct effects on the formation of LRRK2 filaments and their association with cellular structures. Using correlative light microscopy, cryo-electron tomography and sub-tomogram averaging, the authors provide convincing evidence that a Type I inhibitor leads to the extensive decoration of microtubules with LRRK2 in a closed-kinase conformation, and that such decoration is not seen for a type-II inhibitor. The conclusions are consistent with previous work, although the physiological relevance of the work remains somewhat limited due to reliance on overexpression and the use of a rare mutation in a single cell type.
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (eLife)
Abstract
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are a leading contributor to developing familial and idiopathic Parkinson’s disease (PD). Most PD-causing LRRK2 mutations increase the kinase activity, leading to increased phosphorylation of Rab GTPases, disrupting vesicular trafficking, cytoskeletal dynamics, and autophagy. Under homeostatic conditions, the bulk of WT and PD-mutant LRRK2 is found in the cytosol. However, exogenously expressed LRRK2 can form microtubule-associated filaments that have been shown to affect molecular transport along microtubules in vitro. While the physiological relevance of microtubule binding has not been established yet, inhibitors being designed and tested as therapeutics have been shown to either promote or prevent filament formation of LRRK2. In this study, we examine the localization and resulting molecular organization of hyperactive LRRK2-I2020T, a common PD mutant, in cells treated with type I (MLi-2) or type II (GZD-824) kinase inhibitors. Treatment with a type I kinase inhibitor results in extensive LRRK2-I2020T decoration around microtubules and microtubule bundling. Stabilization of LRRK2-I2020T filaments by type I inhibitor treatment allowed us to build a full-length closed-kinase model of LRRK2-I2020T in its cellular environment. Conversely, treatment with a type II inhibitor resulted in minimal microtubule decoration by LRRK2-I2020T compared to Type I inhibitor treated cells. This study provides a structural framework for understanding how type I and type II kinase inhibitors differentially modulate LRRK2 filament formation, demonstrating that type I inhibitor treatment promotes a distinct filament architecture, whereas such assemblies are not observed with type II inhibitors.
Article activity feed
-
**eLife Assessment
**
This study reports important findings by showing that two classes of kinase inhibitors, which stabilise the LRRK2 enzyme in either an active (Type I) or inactive state (Type II), have distinct effects on the formation of LRRK2 filaments and their association with cellular structures. Using correlative light microscopy, cryo-electron tomography and sub-tomogram averaging, the authors provide convincing evidence that a Type I inhibitor leads to the extensive decoration of microtubules with LRRK2 in a closed-kinase conformation, and that such decoration is not seen for a type-II inhibitor. The conclusions are consistent with previous work, although the physiological relevance of the work remains somewhat limited due to reliance on overexpression and the use of a rare mutation in a single cell type. -
Reviewer #1 (Public review):
In this study, the authors set out to determine how two classes of kinase inhibitors, which stabilise a disease-relevant enzyme in either an active (Type I) or inactive state (Type II), influence its organisation and interactions with microtubule filaments in cells. Using the state-of-the-art in-cell structural imaging approaches, they examine how these compounds affect the formation of protein filaments and their association with microtubules, and succeed in defining the underlying structural basis for these differences.
A major strength of the work is the application of in-cell cryo-electron tomography combined with correlative imaging, which enables direct visualisation of protein organisation in a near-native cellular context. The data convincingly demonstrate that the Type I inhibitor compound …
Reviewer #1 (Public review):
In this study, the authors set out to determine how two classes of kinase inhibitors, which stabilise a disease-relevant enzyme in either an active (Type I) or inactive state (Type II), influence its organisation and interactions with microtubule filaments in cells. Using the state-of-the-art in-cell structural imaging approaches, they examine how these compounds affect the formation of protein filaments and their association with microtubules, and succeed in defining the underlying structural basis for these differences.
A major strength of the work is the application of in-cell cryo-electron tomography combined with correlative imaging, which enables direct visualisation of protein organisation in a near-native cellular context. The data convincingly demonstrate that the Type I inhibitor compound stabilising the active state promotes extensive LRRK2 filament formation and microtubule bundling, whereas compounds stabilising the inactive state markedly reduce these interactions. The structural analysis further provides insight into how conformational states relate to filament organisation, including modelling of previously unresolved regions of the protein.
These findings are internally consistent and align well with prior biochemical and structural studies, many of which were performed by the same team.
There are, however, some limitations that should be noted. The experiments rely on overexpression of the I2020T mutant form of the LRRK2 protein, which is a rare variant, in a single cell type (293T cells), which may not fully reflect endogenous behaviour or wild-type LRRK2 in a physiological context. In addition, while the imaging data are compelling, the functional consequences of the observed filament formation and microtubule association remain unclear.
The study therefore provides strong descriptive and structural insight, but more limited evidence linking these observations to cellular or disease-relevant outcomes.
Overall, the authors largely achieve their aims, and the results support their central conclusion that different classes of kinase inhibitors have distinct effects on protein organisation in cells. The work represents an important advance in understanding how small molecules can reshape protein architecture in a cellular environment, with potential implications for therapeutic strategies. The methodological approach will also be of broad interest to the field, as it highlights the power of in-cell structural biology to study dynamic protein assemblies that are difficult to capture using traditional approaches.
-
Reviewer #2 (Public review):
Summary:
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are a major cause of Parkinson's disease. LRRK2 PD-related mutations all result in increased kinase activity. Therefore, LRRK2 has been the focus of the development of kinase inhibitors. So far, two classes of kinase inhibitors have been identified: type 1 LRRK2-specific inhibitors that stabilize LRRK2 in a closed active-like conformation and broad-range type 2 inhibitors that stabilize LRRK2 in an open inactive-like conformation. Basiashvili et al. used here in cell structural biology to study the effect of both type 1 and type 2 inhibitors on the localization and structural conformation of LRRK2-I2020T.
Strengths:
They showed that Type 1 and not Type 2 inhibitors induce LRRK2 filament/ on microtubules. Furthermore, they were able to build a …
Reviewer #2 (Public review):
Summary:
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are a major cause of Parkinson's disease. LRRK2 PD-related mutations all result in increased kinase activity. Therefore, LRRK2 has been the focus of the development of kinase inhibitors. So far, two classes of kinase inhibitors have been identified: type 1 LRRK2-specific inhibitors that stabilize LRRK2 in a closed active-like conformation and broad-range type 2 inhibitors that stabilize LRRK2 in an open inactive-like conformation. Basiashvili et al. used here in cell structural biology to study the effect of both type 1 and type 2 inhibitors on the localization and structural conformation of LRRK2-I2020T.
Strengths:
They showed that Type 1 and not Type 2 inhibitors induce LRRK2 filament/ on microtubules. Furthermore, they were able to build a structural map of full-length LRRK2 I2020T bound to a Type 1 inhibitor in a closed kinase confirmation. Together, this work thus confirms the data of previous studies that showed that LRRK2 Type 1 and 2 inhibitors differently affect filament formation.
Weaknesses:
All conclusions are fully supported by the provided data. However, as the authors indicated themselves, the physiological relevance of LRRK2 microtubule binding is questionable. Furthermore, although the authors used a full-length LRRK2 protein, like in previously published structures, the resolution of the N-terminal domains is rather poor. Therefore, it also remains unclear what we learn from this structure compared to the previously published structures.
-
Reviewer #3 (Public review):
Summary:
This paper describes new insights into the effects of type-I and type-II LRRK2 inhibitors on HEK293T cells that over-express GFP-labeled LRRK2-I2020T. Using correlative light microscopy and cryo-electron tomography, a type-I inhibitor leads to the extensive decoration of microtubules with LRRK2, which is not seen for a type-II inhibitor. Subtomogram averaging reveals that LRRK2 binds to the microtubules in a closed-kinase conformation, with density for the N-terminal arms.
Strengths:
The paper is well written; the CLEM and cryo-ET appear to be done to a high standard. Consequently, I have only minor comments.
Weaknesses:
The resolution of the subtomogram averages is somewhat limited, but the authors have adequately limited the number of degrees of freedom in the fitting of their atomic models by …
Reviewer #3 (Public review):
Summary:
This paper describes new insights into the effects of type-I and type-II LRRK2 inhibitors on HEK293T cells that over-express GFP-labeled LRRK2-I2020T. Using correlative light microscopy and cryo-electron tomography, a type-I inhibitor leads to the extensive decoration of microtubules with LRRK2, which is not seen for a type-II inhibitor. Subtomogram averaging reveals that LRRK2 binds to the microtubules in a closed-kinase conformation, with density for the N-terminal arms.
Strengths:
The paper is well written; the CLEM and cryo-ET appear to be done to a high standard. Consequently, I have only minor comments.
Weaknesses:
The resolution of the subtomogram averages is somewhat limited, but the authors have adequately limited the number of degrees of freedom in the fitting of their atomic models by only allowing rigid-body transformations of separate parts of LRRK2.
The authors should include FSC curves between the rigid-body fitted atomic models and the various sub-tomogram average maps.
-
